AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05259215 — intervention group
Intervention type: OTHER
Intervention: physiotherapy
Description: Standard usual care physiotherapy after stroke
Study NCT01850329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computed-assisted information program
Study NCT01369303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% vaginal gel
Description: Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
Study NCT02150005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Study NCT02235740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib
Description: Afuresertib will be dosed orally in morning, and will be sourced as opaque, white, size 4, 25 mg capsule and size 1, 100 mg capsules.
Study NCT02235740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Intravenous (IV) Carfilzomib will be sourced in the US from commercial stock. It will be a single-use 60 mg vial as a sterile, white to off-white lyophilized cake or powder
Study NCT02235740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib
Description: Intravenous (IV) Carfilzomib will be sourced in the US from commercial stock. It will be a single-use 60 mg vial as a sterile, white to off-white lyophilized cake or powder
Study NCT02100631 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PXVX0200
Study NCT02100631 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0200
Study NCT02100631 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01689038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F17464
Description: Single dose
Study NCT03684655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
Description: \[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
Study NCT03367156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT03367156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO
Study NCT03367156 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT03367156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03367156 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03282396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT01527669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LipoCol Forte capsules
Description: The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
Study NCT01527669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin Tablet
Description: The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
Study NCT06229938 — intervention group
Intervention type: OTHER
Intervention: Passive leg raise manoeuvre
Description: Stroke volume measurements are performed with the Nexfin hemodynamic monitor and the volemic state measurement is based on the principle of the classic passive leg raise test. The Nexfin monitor (Nexfin CC, Edwards Life Sciences, the Netherlands) uses a small inflatable cuff around the index finger of the right hand, to measure the blood pressure, and uses a specific algorithm to calculate the stroke volume.~First a baseline measurement is performed during supine position while the patient is lying in bed. Next, the head end will be lowered until lying flat, and the legs will be passively raised until the lower end of the bed is 30 degrees elevated. The change in stroke volume following the passive leg raise test is used to assess fluid responsiveness. An increase of 10% indicates a fluid responsive status or hypovolemia.
Study NCT04309513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAI score to motivate physical activity
Description: Participants will be encouraged to work up to and maintain the highest PAI score possible, with 100 being the ideal, as measured by a wearable device. Their devices and an accompanying app will provide them with an ongoing real time calculation of the PAI score.
Study NCT04309513 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step Counter to motivate physical activity
Description: Step Counter to motivate physical activity
Study NCT01847209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video-Assisted Thoracic Surgery (VATS) wedge resection
Study NCT02329158 — intervention group
Intervention type: DRUG
Intervention: 6% hydroxyethyl starch
Study NCT00576758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab (RO5072759)
Description: 1000 mg obinutuzumab intravenous (IV) infusion once a week for 4 weeks.
Study NCT03408132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE203799
Description: FE203799 5 mg subcutaneous once weekly
Study NCT00576758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 mg/m\^2 rituximab IV infusion once a week for 4 weeks.
Study NCT00872118 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention for Socially Anxious Drinkers (BISAD)
Description: integrated alcohol and social anxiety individual intervention
Study NCT00872118 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Alcohol Skills Building and Education Program
Description: alcohol-focused group intervention
Study NCT02606305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine
Study NCT02606305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT01498094 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula Oxygen Therapy
Description: Warm humidified oxygen will be delivered at 8 liters/minute via nasal cannulae, at a concentration that maintains saturations greater than 92%.
Study NCT01498094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard low flow oxygen
Description: Standard low flow oxygen will be given to patients to maintain saturations greater than 92%.
Study NCT01548144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib (Xalkori)
Description: Starting dose for Crizotinib - Groups A, B, C: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Expansion Groups Starting Dose: MTD from Phase 1.
Study NCT01548144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Starting Dose for Pazopanib - Groups A, C, D: 200 mg by mouth daily in a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1.
Study NCT01548144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Starting dose for Pemetrexed - Groups B + C: 200 mg/m2 by vein on Day 1 of a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1.~Starting dose for Pemetrexed Group D: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Expansion Group Starting Dose: MTD from Phase 1.
Study NCT03108781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lavender Oil
Description: Lavender Oil twice a day; one month on the face and one month on the legs
Study NCT03108781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lavender Oil
Description: Lavender Oil twice a day; one month on the face and one month on the legs
Study NCT02606305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02606305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Study NCT02606305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT00563173 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CHRONVAC-C®
Description: DNA vaccine, solution for injection, i.m. administration in combination with electroporation
Study NCT02199587 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Presence of medical clown during endocrine test
Study NCT04461392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory exercise test
Description: * Cardiorespiratory exercise test to evaluate the exercise tolerance~* Cardiac imaging for the assessment of the left atrium anatomy and function.
Study NCT01609972 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulator
Description: Non-inferior comparison of implantable spinal cord stimulators
Study NCT01609972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulator
Description: Non-inferior comparison of implantable spinal cord stimulators
Study NCT01431976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamictal
Description: No comparison
Study NCT04601506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice Architecture Nudge
Description: Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record system when they initiate an opioid order for a patient who has not had an opioid prescription within the past six months. The alert provides guidance language about opioid prescribing and prompts the PCP to open the SmartSet to order non-opioid treatment alternatives. When the SmartSet is opened, PCPs can choose to click on a variety of treatment order options, including both non-opioid pharmacological options and non-pharmacological options.~PCPs will also be sent alerts when they initiate an opioid order for a patient will a current opioid prescription. The alerts prompt PCPs to consider tapering the patient's opioid. The alert also displays the MME of the patient's current opioid prescription and automatically calculates what a 10% reduction in MME relative to the current prescription would be. The alert contains options to either cancel the refill order, or to continue with the order.
Study NCT04601506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PMP Integration & Nudge
Description: During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
Study NCT00970944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine Hydrochloride
Description: 184 patients who remain in VS or MCS 4 - 16 weeks post-TBI will be randomized in a stratified fashion to 4 weeks of amantadine (200 - 400 mg/day) followed by a 2-week washout period. The Disability Rating Scale (DRS) will be the primary dependent variable with the Coma Recovery Scale-Revised (CRS-R) serving as a supplementary measure.
Study NCT00970944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered twice daily.
Study NCT02705170 — intervention group
Intervention type: PROCEDURE
Intervention: index of microvascular resistance
Description: Measurement of the index of microvascular resistance in the left anterior descending artery
Study NCT03597867 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Artificial tears for 3 days preoperatively
Study NCT03597867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dicloftil
Description: Dosing of drug 3 days prior to surgery
Study NCT03597867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevanac
Description: Dosing of drug 3 days prior to surgery
Study NCT03597867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indom
Description: Dosing of drug 3 days prior to surgery
Study NCT03597867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yellox
Description: Dosing of drug 3 days prior to surgery
Study NCT03499132 — intervention group
Intervention type: PROCEDURE
Intervention: anesthesia
Description: Different anesthetic procedures
Study NCT03108781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sunflower oil
Description: placebo twice a day (sunflower oil); one month on the face and on month on the legs
Study NCT03108781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sunflower oil
Description: placebo twice a day (sunflower oil); one month on the face and on month on the legs
Study NCT02324543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV on days 4 and 11 of a 21 day cycle
Study NCT02394275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: All eligible patients will receive fecal microbiota transplant
Study NCT01798290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: narrative medicine: reading workshop
Study NCT01798290 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: critical reading
Study NCT03424304 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Excel V™ Laser With Green Genesis
Description: Subject(s) will receive treatments with a Cutera Excel V™ Laser
Study NCT01717248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCS-100
Description: GCS-100 is a modified citrus pectin that binds to and sequesteres circulating galectin-3, a protein that has been shown to promote organ disease (fibrosis).
Study NCT03915067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX® purified neurotoxin complex
Description: BOTOX® superficial intramuscular injections.
Study NCT03915067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX® purified neurotoxin complex
Description: BOTOX® superficial intramuscular injections.
Study NCT01365221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Patients who have received 600 mg loading dose of clopidogrel will receive a reloading dose of 60 mg prasugrel
Study NCT01365221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Patients who have not received a loading dose of clopidogrel will receive a 60 mg loading dose of prasugrel.
Study NCT04568330 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: best support care
Description: Best support care
Study NCT04568330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moisture cream
Description: BSC plus moisture cream
Study NCT04568330 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10% urea-based cream
Description: BSC plus 10% urea-based cream.
Study NCT04643184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Management Program
Description: Joint management between the geriatric and cardiology team of the geriatric syndromes and heart failure. Education of the patient and their caregiver, preparing them for the transition of care.
Study NCT02714179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol was given intravenously in both group at different times
Study NCT03915067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections.
Study NCT01561105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMPACT
Description: IMPACT is a collaborative care management program for late-life depression
Study NCT03260400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a bipolar percutaneous intramuscular electromyography electrode
Description: The device, a bipolar percutaneous intramuscular electromyography electrode, is intended for use in upper-limb amputation patients who have received the regenerative peripheral nerve interface surgical procedure, in order to enable the use of advanced prosthetic arms and hands.
Study NCT03773783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Button and Bead appliance
Description: Button and Bead appliance
Study NCT03773783 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin Block appliance
Description: Twin Block appliance
Study NCT03395678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedling
Description: The exact microneedling settings will be tailored to each patient based on skin type, photodamage, skin thickness based on area of the face. Settings will be adjusted to deliver similar endpoints among all patients. Each participant will receive 5 treatments a month apart.
Study NCT03801252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: intravenous drugs used as prophylactic antibiotics
Study NCT03801252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous saline
Study NCT03801252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: prophylactic antibiotic
Study NCT03778632 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: individualized desensitization exercises
Description: implementing individualized desensitization exercises in standard application of intensive stuttering group therapy for school-age children who stutter
Study NCT03395678 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional non-ablative 1,540nm laser
Description: The exact laser settings will be tailored to each patient based on skin type, photodamage, skin thickness based on area of the face. Settings will be adjusted to deliver similar endpoints among all patients. Each participant will receive 5 treatments a month apart.
Study NCT03778632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individualized desensitization exercises
Description: implementing individualized desensitization exercises in standard application of intensive stuttering group therapy for school-age children who stutter
Study NCT01035788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Behavioral Conjoint Therapy
Description: This intervention combines Cognitive Behavioral Conjoint Therapy for PTSD and mindfulness skills. Cognitive Behavioral Conjoint Therapy for PTSD includes PTSD psychoeducation, communication skills training and cognitive restructuring. Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses.
Study NCT03728088 — intervention group
Intervention type: OTHER
Intervention: Rating scales concerning non-technical attributes
Study NCT01035788 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBCT for PTSD - Communication Skills
Description: This control intervention will provide psychoeducation including the communication skills content from sessions 1-7 of Cognitive Behavioral Conjoint Therapy for PTSD.
Study NCT00077194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Study NCT00657566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: duration of antibiotics
Description: 4 +/- 1 days of antibiotics
Study NCT00657566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: duration of antibiotics
Description: active comparator antibiotics given until 2 days after resolution of fever, elevated white blood cell count, and gastrointestinal dysfunction.
Study NCT02865291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ForConti device
Study NCT03226093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stromal Vascular Fraction
Description: The fat was separated via centrifuge to isolate the SVF and the cells were delivered intraarticularly, intravenously, intrathecally, or intradiscally directly into the same patient
Study NCT00646295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: To measure the IOP (with Goldmann and Pascal DCT tonometers) and OPA (with Pascal DCT) in primary and upright gazes
Description: Pascal Dynamic Contour Tonometer Goldmann Applanation Tonometer
Study NCT02267486 — intervention group
Intervention type: OTHER
Intervention: Standard therapy of Alzheimer Dementia (AD)
Study NCT02267486 — intervention group
Intervention type: OTHER
Intervention: Observation
Study NCT00622193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anamorelin HCl
Description: 50 mg tablet
Study NCT00622193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anamorelin HCl
Description: 100 mg tablet
Study NCT00622193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet
Study NCT02704962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: full-dose olanzapine
Description: trifluoperazine 5mg/d